This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
SMARCA1 / SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 1 · IHC design guide
Design Immunohistochemistry for SMARCA1
Plan chromogenic IHC for SMARCA1 in paraffin sections with the IHC-validated antibody at 1:50–1:200 (datasheet A05676). Compare nuclear and cytoplasmic staining with tissue examples, bearing in mind that staining has low consistency with RNA expression (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
SMARCA1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear and cytoplasmic staining in several tissues (HPA tissue IHC) | |
| Staining pattern | Nuclear and cytoplasmic staining across several cell types (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, heat-mediated (datasheet A05676) | |
| Positive control | Breast+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent (standard IHC practice; not target-specific); target-specific effects are unknown. | |
| Caveat | Staining has low consistency with RNA expression (HPA tissue IHC) | |
| Regulation | Expression regulation not specified (UniProt) | |
| Isoform / epitope | 2 isoforms; epitope coverage is unspecified (UniProt) |
Section 1
Recommended SMARCA1 IHC & IF Protocols
The catalog antibody uses citrate pH 6.0 retrieval (datasheet A05676). One published protocol stains paraffin-embedded soft tissue sarcoma sections (PMC6513346).
| Sample | Paraffin-embedded human lung cancer tissue; fixative not specified (datasheet A05676) |
| Fixation | Image fixative and duration unreported (datasheet A05676); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: Citrate pH 6.0 (datasheet A05676); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-SMARCA1, 1:50-1:200 (datasheet A05676) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | SMARCA1-positive staining in glandular cells of breast (HPA tissue IHC: Medium). HPA tissue profile: Nuclear and cytoplasmic expression in several tissues. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated citrate pH 6.0 retrieval for the catalog antibody (datasheet A05676); the published sarcoma protocol does not specify retrieval conditions (PMC6513346).
Section 2
What Is the Expected SMARCA1 Staining Pattern?
SMARCA1 is a nuclear and chromosome-associated protein with no transmembrane segment (UniProt P28370: subcellular location; topology). In paraffin-section IHC, look for staining in breast glandular cells, lung alveolar cells, brain glia, and cells in testicular seminiferous ducts (HPA tissue IHC: medium staining). HPA reports nuclear and cytoplasmic staining across several tissues, but rates its tissue IHC profile Uncertain because antibody staining has low consistency with RNA expression (HPA tissue IHC: profile; reliability).
| Distinct staining in nuclei of the listed cell populations, with possible cytoplasmic staining. | This fits SMARCA1's nuclear and chromosome location (UniProt P28370: subcellular location) and the reported IHC profile (HPA tissue IHC: nuclear and cytoplasmic expression). Judge intensity against the relevant cell population: the listed positive populations are reported at medium level, not uniformly across every cell in those tissues (HPA tissue IHC: positive cells and levels). |
| Signal is confined to cell borders, extracellular material, or another unexpected compartment, with little convincing nuclear staining. | Investigate background or an antibody-dependent pattern before assigning it to SMARCA1: UniProt places the protein in the nucleus and on chromosomes and reports no transmembrane segment (UniProt P28370: subcellular location; topology). Cytoplasmic staining alone deserves caution rather than automatic rejection, because HPA also reports cytoplasmic tissue IHC staining (HPA tissue IHC: profile). |
| Strong staining appears chiefly in a cell population reported as unstained, while expected positive cells remain faint. | Cross-reactivity or endogenous chromogenic activity is possible; compare cell identity, compartment, and control slides. For example, HPA reports breast glandular cells at medium level and adipocytes as not detected (HPA tissue IHC: breast; adipose tissue). These entries are comparison points, not definitive proof of target absence, because HPA rates the IHC profile Uncertain (HPA tissue IHC: reliability). |
| Brown signal spreads across tissue or blank areas without recognizable cell boundaries or nuclear contrast. | Treat the diffuse deposit as background until controls show otherwise. Check whether it persists when the primary antibody is omitted, and review blocking, washing, and chromogen development as general chromogenic IHC practice. The broad deposit cannot establish a SMARCA1 distribution; HPA's reported staining is described in cells and tissues (HPA tissue IHC: profile). |
| No visible signal appears in a section containing an expected positive population. | First confirm that the expected cells are present: HPA reports medium staining in lung alveolar cells, breast glandular cells, brain glia, and seminiferous-duct cells (HPA tissue IHC: positive cells and levels). Then check the assay controls and general IHC steps. A single blank section does not establish biological absence, particularly with HPA's Uncertain IHC reliability (HPA tissue IHC: reliability). |
💡Expected SMARCA1 appearanceA persuasive positive result is cell-associated staining with clear nuclear signal in a reported medium-staining population, such as breast glandular or lung alveolar cells (UniProt P28370: nuclear location; HPA tissue IHC: positive cells and levels); cytoplasmic signal may accompany it (HPA tissue IHC: profile), whereas diffuse deposits or isolated membrane-like outlines warrant a background check (UniProt P28370: topology; general chromogenic IHC practice).
| Tissue and cell selection | Use the named HPA-positive populations as practical comparison sites; staining is reported at medium level in breast glandular cells, lung alveolar cells, brain glia, and testicular seminiferous-duct cells (HPA tissue IHC: positive cells and levels). HPA reports low tissue RNA specificity and an Uncertain IHC profile, so a tissue label alone does not settle antibody specificity (HPA tissue IHC: RNA specificity; reliability). |
| Antibody validation | The HPA tissue IHC antibody HPA003335 is rated Uncertain for IHC, while HPA064712 is rated Supported for ICC (HPA antibodies: validation status). These are application-specific ratings; use tissue IHC controls to evaluate an IHC result rather than treating the ICC rating as tissue IHC validation (HPA antibodies: validation status; general IHC practice). |
| Sequence and processing | UniProt lists 2 isoforms, no signal peptide or propeptide, and no transmembrane segment (UniProt P28370: isoforms; processing; topology). These facts help frame antibody-epitope questions but do not identify which isoforms an unspecified antibody detects. Target-specific fixation sensitivity and antigen-retrieval requirements are unreported in the supplied UniProt and HPA records. |
| IF/ICC Q&A | Q: What location should an IF/ICC image support? A: Predominantly nucleoplasmic signal; HPA also reports vesicles as an additional location (HPA subcellular: supported nucleoplasm; approved vesicles). This ICC observation is useful for localization comparison, while HPA's tissue IHC profile separately reports nuclear and cytoplasmic staining with Uncertain reliability (HPA tissue IHC: profile; reliability). |
| Situation | Likely cause | Next action |
|---|---|---|
| Expected positive cells are blank. | The target population may be absent from the section, or a general IHC step may have failed; the chosen HPA-positive populations are reported at medium level (HPA tissue IHC: positive cells and levels). | Verify the cell population on the counterstained section, run a suitable positive-control section, then review retrieval, primary incubation, and detection against the antibody's documented IHC procedure (general IHC practice). Do not infer a SMARCA1-specific retrieval requirement from HPA staining levels. |
| Signal is widespread and lacks cellular structure. | Nonspecific binding, insufficient washing, or excessive chromogen development can produce diffuse background (general chromogenic IHC practice). | Compare a primary-omission control, inspect washes and blocking, and shorten chromogen development if the control also stains (general chromogenic IHC practice). Reassess nuclear and cell-specific staining only after background is controlled (UniProt P28370: nuclear location; HPA tissue IHC: positive cells). |
| Primary-omission control still develops color. | Endogenous detection activity or another reagent-dependent deposit is plausible when color forms without primary antibody (general chromogenic IHC practice). | Check the detection system's endogenous-activity block and reagent-only controls before interpreting cellular color (general chromogenic IHC practice). Do not attribute control-slide color to SMARCA1. |
| Only cytoplasm stains in the expected cells. | HPA reports cytoplasmic as well as nuclear tissue staining, but UniProt places SMARCA1 in the nucleus and on chromosomes (HPA tissue IHC: profile; UniProt P28370: subcellular location). | Compare the nuclear counterstain and a second well-controlled section. Record the cytoplasmic-only result as ambiguous if nuclear signal remains absent, given HPA's Uncertain tissue IHC reliability (HPA tissue IHC: reliability; general IHC practice). |
| Reported negative cells stain more strongly than expected positive cells. | Cell misidentification, cross-reactivity, or endogenous detection activity may explain the mismatch (general IHC practice); HPA reports adipocytes as not detected and breast glandular cells at medium level (HPA tissue IHC: adipose tissue; breast). | Confirm cell identity and compare primary-omission and positive-control sections. Treat the HPA negative entry as a reference observation rather than a universal exclusion rule, because the tissue IHC profile is Uncertain (HPA tissue IHC: reliability). |
| Signal appears as isolated membrane-like outlines. | A membrane-confined pattern conflicts with the reported nuclear and chromosome location and lack of transmembrane segment (UniProt P28370: subcellular location; topology). | Inspect the same cells for convincing nuclear staining and compare control sections; investigate edge staining or detection background before scoring the outlines as positive (general chromogenic IHC practice). |
Experiment evidence
IHC & IF images showing SMARCA1 staining
A05676 · IHCImmunohistochemistry of paraffin-embedded human lung cancer using SMARCA1 Rabbit pAb at dilution of 1:100 .Perform high pressure antigen ret
A05676 · IHCImmunohistochemistry of paraffin-embedded human esophageal cancer using SMARCA1 Rabbit pAb at dilution of 1:100 .Perform high pressure antig
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000102038-SMARCA1/tissue/cerebral+cortex#imid_1109496
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000102038-SMARCA1/tissue/colon#imid_1109438
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000102038-SMARCA1/tissue/liver#imid_1109439
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000102038-SMARCA1/tissue/kidney#imid_1109432
HPA · ICC-IF Hep-G2Human Protein Atlas immunofluorescence, Hep-G2, antibody HPA064712; green = SMARCA1, blue = nucleus, red = microtubules.
HPA · ICC-IF Hep-G2Human Protein Atlas immunofluorescence, Hep-G2, antibody HPA064712; green = SMARCA1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for SMARCA1 IHC & IF
🧪Run breast first and score glandular-cell nuclei for medium staining (HPA: Breast glandular cells, Medium; UniProt P28370: nucleus). Use adipose tissue as the negative tissue (HPA: Adipocytes, Not detected); if adipocytes are present on the breast slide, their nuclei should lack specific staining, though that internal comparison needs confirmation (HPA: Adipose tissue adipocytes, Not detected).
Positive control tissue: Breast (Glandular cells, HPA Medium)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show SMARCA1 in Hep-G2, SH-SY5Y, U2OS, with annotated localisation: Nucleoplasm (supported) (HPA subcellular).
Technical controls: Include a no-primary (secondary-only) control, a concentration-matched rabbit polyclonal IgG isotype control, and SMARCA1-knockout material as a biological negative when available (selected caption: rabbit pAb; standard IHC practice). Quench endogenous peroxidase for chromogenic detection and assess endogenous biotin if using avidin–biotin detection (standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A05676 paraffin-section caption does not state a fixative (selected tissue-IHC caption). That caption reports high-pressure retrieval in 10 mM citrate, pH 6.0, before IHC at 1:100; frozen-section performance is unreported, while HPA ICC-IF supports mainly nucleoplasmic localization, so the supplied evidence does not establish that frozen sections or IF are easier (selected tissue-IHC caption; HPA: subcellular). In breast sections, score glandular nuclei rather than adipose spaces, which can distort area-based assessment (HPA: Breast glandular cells, Medium; standard histology practice).
HPA tissue IHC evidence for SMARCA1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Uncertain — Low consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Breast | Glandular cells | Medium | Protein (IHC) | HPA → |
| Caudate | Glial cells | Medium | Protein (IHC) | HPA → |
| Cerebellum | Cells in molecular layer | Medium | Protein (IHC) | HPA → |
| Cerebral cortex | Glial cells | Medium | Protein (IHC) | HPA → |
| Hippocampus | Glial cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
| Cervix | Glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced SMARCA1 IHC Tips
Use nuclear localization, the selected antibody’s paraffin-section evidence, and tissue controls to troubleshoot SMARCA1 staining (UniProt P28370; datasheet A05676; HPA tissue IHC).
How should I adjust retrieval when SMARCA1 staining is weak in paraffin sections?
Use high-pressure, heat-mediated retrieval in 10 mM citrate buffer at pH 6.0 for SMARCA1 paraffin-section IHC (datasheet A05676). The selected antibody’s lung cancer image used this retrieval and a 1:100 primary dilution, providing a starting point for comparison (datasheet A05676). If nuclear staining is weak, vary heating duration on matched sections while holding antibody dilution and detection conditions constant, and inspect tissue morphology after each trial (standard IHC practice). Compare with a no-primary control and a section containing an expected positive cell population, such as lung alveolar cells; tissue staining consistency is uncertain, so neither control alone establishes specificity (HPA tissue IHC).
Could fixation explain absent or patchy SMARCA1 staining?
Target-specific fixation sensitivity is unknown: the selected paraffin-section caption does not state a fixative (datasheet A05676). Record the fixative, fixation duration, section age, and processing history for each specimen before comparing staining across cases (standard IHC practice). For newly prepared specimens, keep fixation and processing consistent, then assess matched sections with the specified 10 mM citrate retrieval at pH 6.0 (datasheet A05676; standard IHC practice). If signal varies, examine morphology and nuclear staining in comparable cells before attributing the difference to SMARCA1 expression; nuclear localization is expected, but fixation effects cannot be inferred from that localization (UniProt P28370; standard IHC practice).
Should I count cytoplasmic SMARCA1 staining as a positive IHC result?
Prioritize staining that resolves within intact nuclei because SMARCA1 is annotated in the nucleus and on chromosomes (UniProt P28370). HPA reports nuclear and cytoplasmic tissue staining, but rates its tissue IHC reliability uncertain because staining and RNA expression show low consistency (HPA tissue IHC). Compare nuclear signal with cytoplasmic signal in the same cell population and review the hematoxylin counterstain to establish cell boundaries (standard IHC practice). Treat cytoplasmic-only staining cautiously, especially when it is diffuse or appears in a no-primary control; repeat staining with the selected retrieval and antibody conditions before assigning a biological interpretation (datasheet A05676; standard IHC practice).
Can the IHC stain distinguish SMARCA1 isoforms or phosphorylation states?
SMARCA1 has 2 listed isoforms and reported phosphorylation at residues 116, 119, and 942 (UniProt P28370). The supplied antibody caption identifies neither an epitope nor isoform selectivity, so its paraffin-section staining cannot establish which isoform or modification is present (datasheet A05676). Check the antibody’s epitope documentation before comparing specimens, and interpret any signal as total detectable antigen unless isoform or modification specificity has been demonstrated (standard IHC practice). When resolving these distinctions matters, compare staining with an independently characterized, epitope-defined reagent and an appropriate perturbation control on matched sections; changes in chromogenic intensity alone cannot identify a phosphorylation state (standard IHC practice).
How can I check SMARCA1 localization by multiplex IF alongside tissue IHC?
For a separate IF experiment, multiplex SMARCA1 with a validated marker of the expected cell type, such as alveolar cells in lung, and inspect nuclear overlap within marker-positive cells (HPA tissue IHC; UniProt P28370). Choose a far-red fluorophore when tissue autofluorescence compromises shorter wavelengths, and include single-stain and no-primary controls to assess bleed-through and background (standard IF practice). SMARCA1 has no transmembrane segment and is annotated in the nucleus, so permeabilize cellular membranes to access a nuclear epitope while preserving nuclear morphology; the antibody’s exact epitope is unreported here (UniProt P28370; standard IF practice). Optimize IF fixation and permeabilization independently because the supplied paraffin-section caption does not specify IF conditions (datasheet A05676).
What should I change when SMARCA1 chromogenic IHC has diffuse background?
First compare the stained section with a no-primary control and check whether background follows tissue folds, cut edges, or damaged areas (standard IHC practice). For peroxidase-based chromogenic detection, verify the endogenous peroxidase block, then review secondary reagent specificity, wash stringency, and DAB development time (standard IHC practice). Titrate the primary around the documented 1:100 lung cancer image condition on matched sections, changing one variable at a time (datasheet A05676; standard IHC practice). Score nuclear signal separately from diffuse cytoplasmic color: nuclear localization is expected, whereas the available HPA tissue staining has uncertain reliability (UniProt P28370; HPA tissue IHC).
How should I quantify SMARCA1 staining across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and regions of interest before scoring, excluding folds, necrosis, and poorly preserved edges (standard IHC practice). For intact nuclei, record the percentage of positive cells and staining intensity, then calculate a nuclear H-score from intensity categories 0–3 if the study needs a combined measure (standard IHC practice; UniProt P28370). Normalize counts to the number of evaluable nuclei in each region, or report positive-cell density per mm² with the sampled area stated (standard IHC practice). Keep retrieval, the documented 1:100 starting dilution, detection, and image settings consistent across comparison sections; report cytoplasmic staining separately because HPA tissue IHC reliability is uncertain (datasheet A05676; HPA tissue IHC).
How can I distinguish true SMARCA1 staining from section artefacts?
A plausible positive pattern is nuclear staining in intact cells, consistent with SMARCA1’s nuclear and chromosomal annotation (UniProt P28370). Compare the stained cell type with documented tissue observations, such as medium staining in lung alveolar cells, while recognizing that HPA rates its tissue IHC reliability uncertain (HPA tissue IHC). Review cells beside necrosis, section edges, and folds separately, and check a no-primary control for chromogen arising from endogenous enzyme activity or detection reagents (standard IHC practice). If staining is predominantly cytoplasmic, confined to damaged areas, or inconsistent across matched sections, repeat the selected citrate retrieval and verify nuclear morphology before calling the specimen positive (datasheet A05676; standard IHC practice).
Boster reagents
Best SMARCA1 / SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 1 IHC Antibodies
A05676 has real IHC images from paraffin-embedded human lung and esophageal cancer (catalog image captions). Human, mouse, and rat reactivity is listed; IF/ICC data are absent (catalog: reactivity and applications).
Real IHC data
Anti-SMARCA1 Antibody
Cat # A05676
A05676 is listed for IHC and has images of paraffin-embedded human lung and esophageal cancer sections (catalog: applications and IHC image captions). Human, mouse, and rat reactivity is listed, but the supplied images show human tissue only (catalog: reactivity and IHC image captions).
Which to pick: For tissue IHC, choose A05676: its paraffin-section images use 1:100 antibody dilution and high-pressure retrieval in 10 mM citrate buffer at pH 6.0; the fixative is unreported (catalog: IHC image captions). No SKU here is listed for IF/ICC, so there is no IF/ICC pick (catalog: applications). For mouse or rat IHC, A05676 is the only listed option based on stated reactivity, although its supplied images show human tissue; it is a rabbit polyclonal antibody (catalog: reactivity, IHC image captions, and host/clonality).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P28370 (SMCA1_HUMAN, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 1).
- Human Protein Atlas. SMARCA1 tissue IHC expression (reliability: Uncertain).
- Human Protein Atlas. SMARCA1 subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to vesicles..
- Human Protein Atlas. SMARCA1 antibody validation summary (2 antibodies).
- Loss of Expression of a Novel Chromatin Remodeler SMARCA1 in Soft Tissue Sarcoma. Journal of cytology & histology 2018 — PMC6513346.
- PubMed PMID:1408766 — UniProt-cited evidence.
- PubMed PMID:15310751 — UniProt-cited evidence.
- PubMed PMID:15772651 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for SMARCA1 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 1). Expected localisation Nuclear and cytoplasmic staining in several tissues (HPA tissue IHC). Antigen retrieval: Citrate pH 6.0 HIER, heat-mediated (datasheet A05676). Validated IHC antibody: A05676 at 1:50-1:200 (the product's own IHC validation image is shown). Controls (HPA): positive Breast (Glandular cells); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Paraffin-embedded human lung cancer tissue; fixative not specified (datasheet A05676); 2. Fixation: Image fixative and duration unreported (datasheet A05676); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: Citrate pH 6.0 (datasheet A05676); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-SMARCA1, 1:50-1:200 (datasheet A05676); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent (standard IHC practice; not target-specific); target-specific effects are unknown.; Caveat: Staining has low consistency with RNA expression (HPA tissue IHC); Isoform / epitope: 2 isoforms; epitope coverage is unspecified (UniProt); Regulation: Expression regulation not specified (UniProt). Evidence: UniProt P28370, HPA tissue IHC · Uncertain, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to…, Datasheet A05676, PMC6513346. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/SMARCA1/immunohistochemistry-ihc-guide.